United Health Products Advances FDA Approval Process for Novel Hemostatic Agent
Medical device company United Health Products has made significant progress in its FDA approval process for CelluSTAT, a natural bleeding control agent, while securing funding and pursuing an uplisting to OTCQB. The development could lead to a new option in surgical bleeding control.
United Health Products (OTCPK: UEEC) has reached important milestones in its quest for FDA approval of CelluSTAT, its patented Neutralized Regenerated Cellulose hemostatic agent, marking potential advancement in surgical bleeding control solutions. The company has successfully addressed FDA concerns regarding preclinical testing protocols and plans to submit additional responses to the agency's comments in early February.
The company is making parallel progress on multiple fronts, having identified surgical sites through a large, multi-state healthcare provider for conducting organ space surgical procedures. These developments, combined with ongoing contract negotiations with site operators and a Central IRB, position the company to complete its clinical study report by mid-summer, assuming all processes proceed as planned.
To support these initiatives, United Health Products has secured over $400,000 through private placement transactions with existing shareholders and is pursuing additional funding. The company has also applied for an uplisting from the OTCPK to the OTCQB exchange, a move that could potentially increase visibility and accessibility to investors.
The advancement of CelluSTAT through the FDA approval process is significant for the medical device industry, as successful commercialization would introduce a new all-natural option for controlling mild to moderate bleeding during surgical procedures. However, the company notes that FDA approval is not guaranteed, and the timeline for potential market entry remains subject to regulatory review.